American Epilepsy Society Meeting 2024.Safety, Tolerability, and Pharmacokinetics of Novel 5-HT2C Agonist BMB-101 (Phase I Clinical Study)American Epilepsy Society Meeting 2024. BMB-101 and Biased 5-HT2C Agonism: A Novel Approach for Sustained Epilepsy Management
Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). BMB-101: A selective 5-HT2C agonist for the treatment of rare epilepsies.
Society for Neuroscience 2024 Annual Meeting (Chicago). Poster: Novel 5-HT2A selective agonists with well-characterized PK profile and short duration of action.
Society for Neuroscience 2024 Annual Meeting (Chicago), Satellite NIH Forum. Poster: Selective 5-HT2C Agonists for the Treatment of Rare Epileptic Disorders
Society for Neuroscience 2024 Annual Meeting (Chicago). Poster: Novel 5-HT2A/2C mixed and partial agonist and its efficacy in preclinical pain models
"*" indicates required fields
×